# Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation

Study · id `cardio:ct-nct07626411` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07626411](<https://clinicaltrials.gov/study/NCT07626411>), retrieved 18 November 2026. No person wrote or checked this page.

Also called: NCT07626411

Browse, organ or system: Heart; Brain  
Browse, condition area: Stroke; Heart rhythm problems  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 15364 participants.

## Technical summary

Registry record NCT07626411. Randomized; quadruple masking; primary purpose prevention. Start 2026-08-10 (actual); primary completion 2029-09-11 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose prevention
- Phase: Phase 3
- Enrolled: 15364 participants (planned count; ClinicalTrials.gov record NCT07626411, source copy `cardio:ctgov-nct07626411-2026-11-18`, retrieved 2026-11-18)
- Started: 2026-08-10 (actual) (ClinicalTrials.gov record NCT07626411, source copy `cardio:ctgov-nct07626411-2026-11-18`, retrieved 2026-11-18)
- Primary completion: 2029-09-11 (anticipated) (ClinicalTrials.gov record NCT07626411, source copy `cardio:ctgov-nct07626411-2026-11-18`, retrieved 2026-11-18)
- Completion: 2029-12-10 (anticipated) (ClinicalTrials.gov record NCT07626411, source copy `cardio:ctgov-nct07626411-2026-11-18`, retrieved 2026-11-18)
- Countries: United States; Canada; Japan (ClinicalTrials.gov record NCT07626411, source copy `cardio:ctgov-nct07626411-2026-11-18`, retrieved 2026-11-18)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07626411-2026-11-18`, retrieved 2026-11-18)

## The registry's words

- Brief title: Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation
- Acronym: ROXI-EVEREST
- Condition: Atrial Fibrillation (AF)
- Intervention (Drug): REGN7508
- Intervention (Drug): Apixaban
- Intervention (Drug): Placebo
- Lead sponsor: Regeneron Pharmaceuticals
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Arrhythmia (heart rhythm problems) (`cardio:arrhythmia`)
- Registry condition terms include this condition: Atrial fibrillation (AF) (`cardio:atrial-fibrillation`)
- Registry condition terms include this condition: Stroke (`core:stroke`)
- Registry intervention name matches this record: Apixaban (`cardio:apixaban`)
- Registry lists this organization as the lead sponsor: Regeneron Pharmaceuticals (`cardio:org-regeneron-pharmaceuticals`)

## Provenance

Content hash: 29eb452677ab9ca6b1894a9c3201cd346c08bf605fbd86f48a3ddd1280af951c
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
